CL2013003602A1 - Compuestos derivados de benzoimidazol (indol) de analogos de espirocarbamato o sus sales como antagonistas de trpv4; composicion farmaceutica que los comprende, util para el tratamiento de aterosclerosis, trastornos relacionados con edema intestinal, trastornos pulmonares, enfermedad cardiovascular, disfuncion renal, osteoartritis, entre otras. - Google Patents
Compuestos derivados de benzoimidazol (indol) de analogos de espirocarbamato o sus sales como antagonistas de trpv4; composicion farmaceutica que los comprende, util para el tratamiento de aterosclerosis, trastornos relacionados con edema intestinal, trastornos pulmonares, enfermedad cardiovascular, disfuncion renal, osteoartritis, entre otras.Info
- Publication number
- CL2013003602A1 CL2013003602A1 CL2013003602A CL2013003602A CL2013003602A1 CL 2013003602 A1 CL2013003602 A1 CL 2013003602A1 CL 2013003602 A CL2013003602 A CL 2013003602A CL 2013003602 A CL2013003602 A CL 2013003602A CL 2013003602 A1 CL2013003602 A1 CL 2013003602A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- benzoimidazole
- osteoarthritis
- atherosclerosis
- indole
- Prior art date
Links
- UGPUQHVITYCTEV-UHFFFAOYSA-N 1h-benzimidazole;1h-indole Chemical compound C1=CC=C2NC=CC2=C1.C1=CC=C2NC=NC2=C1 UGPUQHVITYCTEV-UHFFFAOYSA-N 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 206010058061 Gastrointestinal oedema Diseases 0.000 title 1
- 208000019693 Lung disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 201000008482 osteoarthritis Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000008085 renal dysfunction Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498110P | 2011-06-17 | 2011-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003602A1 true CL2013003602A1 (es) | 2014-07-04 |
Family
ID=47558389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003602A CL2013003602A1 (es) | 2011-06-17 | 2013-12-16 | Compuestos derivados de benzoimidazol (indol) de analogos de espirocarbamato o sus sales como antagonistas de trpv4; composicion farmaceutica que los comprende, util para el tratamiento de aterosclerosis, trastornos relacionados con edema intestinal, trastornos pulmonares, enfermedad cardiovascular, disfuncion renal, osteoartritis, entre otras. |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2720546B1 (en) | 2011-06-17 | 2016-04-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Spiro-cyclic trpv4 antagonists |
| US8927585B2 (en) * | 2011-06-17 | 2015-01-06 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonists |
| WO2013146754A1 (ja) | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体 |
| WO2015046193A1 (ja) | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体 |
| CN109153672B (zh) * | 2016-05-19 | 2021-12-07 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Trpv4拮抗剂 |
| US10968209B2 (en) | 2016-05-19 | 2021-04-06 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonist |
| TN2019000087A1 (en) | 2016-10-03 | 2020-07-15 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018185701A1 (en) | 2017-04-06 | 2018-10-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists as antitussive agents |
| CA3081424A1 (en) * | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid x receptor modulators |
| WO2021170811A1 (en) | 2020-02-27 | 2021-09-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treating eye disease using trpv4 antagonists |
| JP7692219B2 (ja) | 2020-04-30 | 2025-06-13 | ラクオリア創薬株式会社 | Ｔｒｐｖ４拮抗薬としてのピリミジン－４（３ｈ）－オン誘導体 |
| CN111704613B (zh) * | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
| JPWO2022014707A1 (https=) * | 2020-07-16 | 2022-01-20 | ||
| WO2024011214A1 (en) | 2022-07-08 | 2024-01-11 | Actio Biosciences, Inc. | Therapeutic compounds and methods |
| CN120641413A (zh) * | 2023-04-18 | 2025-09-12 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217446A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217452A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217439A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| CN120435476A (zh) * | 2023-04-18 | 2025-08-05 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2025014818A1 (en) * | 2023-07-07 | 2025-01-16 | Actio Biosciences, Inc. | Solid forms of gsk2798745, a trpv4 antagonist |
| CN117945917A (zh) * | 2023-12-26 | 2024-04-30 | 衢州康鹏化学有限公司 | 一种3-氟-4-硝基苯甲酸的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE482945T1 (de) * | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
| CA2531619A1 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| WO2007059608A1 (en) * | 2005-11-23 | 2007-05-31 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| WO2007067756A2 (en) | 2005-12-08 | 2007-06-14 | Amphora Discovery Corporation | Certain chemical entities, compositions, and methods for modulating trpv1 |
| AU2006327181A1 (en) * | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
| TW200819457A (en) * | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
| PE20081735A1 (es) * | 2007-02-01 | 2009-01-18 | Glaxo Group Ltd | Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios |
| GB0707934D0 (en) * | 2007-04-24 | 2007-05-30 | Glaxo Group Ltd | Chemical compounds |
| EP2185538A2 (en) * | 2007-08-09 | 2010-05-19 | Abbott Laboratories | Tetrahydropyridine carboxamide derivatives as trpvl antagonists |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
| JP5607046B2 (ja) * | 2008-07-25 | 2014-10-15 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｔｒｐｖ４拮抗薬 |
| JP2012006837A (ja) * | 2008-09-30 | 2012-01-12 | Mochida Pharmaceut Co Ltd | ２−インドールアクリルアミド類縁体 |
| WO2012024183A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| US8927585B2 (en) * | 2011-06-17 | 2015-01-06 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonists |
| EP2720546B1 (en) * | 2011-06-17 | 2016-04-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Spiro-cyclic trpv4 antagonists |
-
2012
- 2012-06-14 JO JOP/2012/0159A patent/JO3154B1/ar active
- 2012-06-15 TW TW101121449A patent/TWI538912B/zh active
- 2012-06-15 HU HUE12814591A patent/HUE029594T2/en unknown
- 2012-06-15 JP JP2014516020A patent/JP5969017B2/ja active Active
- 2012-06-15 WO PCT/US2012/042622 patent/WO2013012500A1/en not_active Ceased
- 2012-06-15 DK DK12814591.9T patent/DK2721016T3/en active
- 2012-06-15 UA UAA201400152A patent/UA113963C2/uk unknown
- 2012-06-15 US US14/125,378 patent/US9187464B2/en active Active
- 2012-06-15 SG SG2013086483A patent/SG195106A1/en unknown
- 2012-06-15 ES ES16162808T patent/ES2688733T3/es active Active
- 2012-06-15 BR BR112013032391-4A patent/BR112013032391B1/pt active IP Right Grant
- 2012-06-15 RS RS20160417A patent/RS54858B1/sr unknown
- 2012-06-15 CA CA2839743A patent/CA2839743C/en active Active
- 2012-06-15 HR HRP20160539TT patent/HRP20160539T1/hr unknown
- 2012-06-15 UY UY0001034138A patent/UY34138A/es not_active Application Discontinuation
- 2012-06-15 EP EP16162808.6A patent/EP3121177B1/en active Active
- 2012-06-15 SI SI201230564A patent/SI2721016T1/sl unknown
- 2012-06-15 PH PH1/2013/502463A patent/PH12013502463A1/en unknown
- 2012-06-15 PT PT128145919T patent/PT2721016E/pt unknown
- 2012-06-15 MY MYPI2013702447A patent/MY173521A/en unknown
- 2012-06-15 ES ES12814591T patent/ES2569193T3/es active Active
- 2012-06-15 PE PE2013002807A patent/PE20141943A1/es active IP Right Grant
- 2012-06-15 EP EP12814591.9A patent/EP2721016B1/en active Active
- 2012-06-15 PL PL12814591T patent/PL2721016T3/pl unknown
- 2012-06-15 AR ARP120102143A patent/AR086958A1/es active IP Right Grant
- 2012-06-15 CN CN201280039690.0A patent/CN103732583B/zh active Active
- 2012-06-15 KR KR1020147000958A patent/KR101870003B1/ko active Active
- 2012-06-15 ME MEP-2016-120A patent/ME02416B/me unknown
- 2012-06-15 MX MX2013014898A patent/MX337440B/es active IP Right Grant
- 2012-06-15 EA EA201490037A patent/EA023616B1/ru not_active IP Right Cessation
- 2012-06-15 AU AU2012284540A patent/AU2012284540B2/en active Active
-
2013
- 2013-11-22 ZA ZA2013/08816A patent/ZA201308816B/en unknown
- 2013-12-09 IL IL229872A patent/IL229872A/en active IP Right Grant
- 2013-12-11 CO CO13290152A patent/CO6821953A2/es active IP Right Grant
- 2013-12-13 MA MA36564A patent/MA35184B1/fr unknown
- 2013-12-16 CL CL2013003602A patent/CL2013003602A1/es unknown
- 2013-12-17 DO DO2013000307A patent/DOP2013000307A/es unknown
- 2013-12-17 CR CR20130671A patent/CR20130671A/es unknown
-
2016
- 2016-05-31 SM SM201600150T patent/SMT201600150B/it unknown
- 2016-06-21 CY CY20161100556T patent/CY1117792T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003602A1 (es) | Compuestos derivados de benzoimidazol (indol) de analogos de espirocarbamato o sus sales como antagonistas de trpv4; composicion farmaceutica que los comprende, util para el tratamiento de aterosclerosis, trastornos relacionados con edema intestinal, trastornos pulmonares, enfermedad cardiovascular, disfuncion renal, osteoartritis, entre otras. | |
| CL2014001212A1 (es) | Compuestos heterobiciclicos condensados, inhibidores de fosfodiesterasa tipo 10a; composicion farmaceutica que los comprende; y metodo para tratar un trastorno seleccionado entre trastornos neurologicos y trastornos psiquiatricos. | |
| CL2014003277A1 (es) | Compuestos derivados heterociclicos sustituidos por carboxamida o sulfonamida, como moduladores para el receptor nuclear huerfano rorgama; composicion farmaceutica que los comprende, util para el tratamiento de artritis reumatoide, lupus eritematoso, psoriasis, esclerosis multiple, diabetes tipo 1, colitis ulcerosa, enfermedad pulmonar obstructiva cronica, entre otras. | |
| CO6741217A2 (es) | Modulares de receptor de glucagón | |
| EA201200239A1 (ru) | Бициклические арильные аналоги сфингозин 1-фосфата | |
| GT201600085A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CL2016002011A1 (es) | Derivados de heterociclos bicíclicos condensados sustituidos con 2-(het)arilo como agentes para combatir parásitos | |
| CL2014002541A1 (es) | Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades. | |
| ECSP13012790A (es) | Imidazolilimidazoles condensados como compuestos antivirales | |
| CO6990728A2 (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| CL2014000642A1 (es) | Compuestos derivados de indazol-3-carboxamidas, como inhibidores de la ruta de señalizacion de wnt/b-catenina; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, artritis reumatoide, infecciones micoticas y viricas, enfermedad de parkinson, un trastorno fibrotico, entre otras enfermedades. | |
| CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
| CL2015000956A1 (es) | Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros. | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| ECSP11011517A (es) | Compuestos antivirales | |
| CL2014001205A1 (es) | Compuestos derivados de purina, sus sales y solvatos farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tal como infecciones viricas, trastornos inmunitarios o inflamatorios. | |
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| GT201300123A (es) | Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-(2,3-d)-pirimidin-6-carboxilico y procesos para su elaboracion | |
| DOP2010000149A (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| PL2593452T3 (pl) | Związki heterocykliczne będące agonistami receptora IP | |
| CL2013002546A1 (es) | Compuestos derivados de benzodioxano con actividad inhibidora de leucotrieno a4 hidrolasa(lat4h), composicion farmaceutica que los comprende, uso para preparar un medicamento para el tratamiento de enfermedades cardiovasculares tales como ateroesclerosis, infarto de miocardio, apoplejia, aneurisma de aorta, hipertension pulmonar arterial, entre otras. | |
| CL2013003512A1 (es) | Compuestos derivados de 7-(heterociclilo, arilo o heteroarilo) de piridopirazinas o sus sales; composicion farmaceutica que los comprende, utiles para el tratamiento de una enfermedad mediada por ptk quinasa tales como asma alergica, rinitis alergica, artritis reumatoide, esclerosis multiple, lupus, leucopenia, entre otras enfermedades. | |
| EA201171488A1 (ru) | Lxr модуляторы | |
| DK3103797T3 (da) | 2,5-dioxoimidazolidin-1-yl-3-phenylurinstofderivater som formylpeptidreceptor-lignende-1- (fprl-1) receptormodulatorer |